An open-label phase 2 study to explore the durability of effect, and safety of once-daily oral ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor, for the symptomatic treatment of neurogenic orthostatic hypotension in subjects with synucleinopathies

Authors
Category Primary study
JournalNeurology
Year 2020
This article has no abstract
Epistemonikos ID: 8825827521d0a89ee7d3be84f5bad77c16643acc
First added on: Feb 12, 2025